Dawn L Hershman1, Alfred I Neugut2, Jin Joo Shim2, Sherry Glied2, Wei-Yann Tsai2, Jason D Wright2. 1. Columbia University College of Physicians and Surgeons and Mailman School of Public Health; and New York Presbyterian Hospital, New York, NY dlh23@columbia.edu. 2. Columbia University College of Physicians and Surgeons and Mailman School of Public Health; and New York Presbyterian Hospital, New York, NY.
Abstract
PURPOSE: Since 2004, concerns about the safety of erythropoiesis-stimulating agents (ESAs) have resulted in label changes and restrictions on their use. We examined changes in ESA use and blood transfusions over time. METHODS: The SEER-Medicare database was used to identify patients age ≥ 65 years with breast, lung, prostate, ovary, or colon cancer, diagnosed between 2000 and 2007, who had a chemotherapy claim after their cancer diagnosis. We calculated the mean number of ESA claims per patient per year. Follow-up claims were available through 2008. We used multivariable logistic regression models to analyze the association of ESA use and extended ESA use with clinical and demographic variables. RESULTS: Among 121,169 patients identified, 46,063 (38%) received an ESA. ESA use increased from 12.4% to 16.2% by 2006 and then decreased to 7.9% by 2008. Similarly, the mean number of ESA claims per patient decreased steadily over the entire timeframe. The annual percentage of patients undergoing transfusion remained relatively constant (9% to 10%). In a Cox proportional hazards time-dependent model, ESA use was positively associated with black race (odds ratio [OR], 1.11; 95% CI, 1.07 to 1.15), metropolitan location (OR, 1.17; 95% CI, 1.13 to 1.21), metastatic disease (OR, 1.39; 95% CI, 1.35 to 1.41), female sex (OR, 1.17; 95% CI, 1.14 to 1.20), > one comorbidity (OR, 1.29; 95% CI, 1.25 to 1.32), and tumor type. The number of denied claims increased over time. CONCLUSION: Our study demonstrated a rapid decline in the percentage of patients treated with ESAs after changes to reimbursement policy, but not after warnings about use. Reimbursement restrictions of other overused or off-label drugs may help reduce health care expenditures.
PURPOSE: Since 2004, concerns about the safety of erythropoiesis-stimulating agents (ESAs) have resulted in label changes and restrictions on their use. We examined changes in ESA use and blood transfusions over time. METHODS: The SEER-Medicare database was used to identify patients age ≥ 65 years with breast, lung, prostate, ovary, or colon cancer, diagnosed between 2000 and 2007, who had a chemotherapy claim after their cancer diagnosis. We calculated the mean number of ESA claims per patient per year. Follow-up claims were available through 2008. We used multivariable logistic regression models to analyze the association of ESA use and extended ESA use with clinical and demographic variables. RESULTS: Among 121,169 patients identified, 46,063 (38%) received an ESA. ESA use increased from 12.4% to 16.2% by 2006 and then decreased to 7.9% by 2008. Similarly, the mean number of ESA claims per patient decreased steadily over the entire timeframe. The annual percentage of patients undergoing transfusion remained relatively constant (9% to 10%). In a Cox proportional hazards time-dependent model, ESA use was positively associated with black race (odds ratio [OR], 1.11; 95% CI, 1.07 to 1.15), metropolitan location (OR, 1.17; 95% CI, 1.13 to 1.21), metastatic disease (OR, 1.39; 95% CI, 1.35 to 1.41), female sex (OR, 1.17; 95% CI, 1.14 to 1.20), > one comorbidity (OR, 1.29; 95% CI, 1.25 to 1.32), and tumor type. The number of denied claims increased over time. CONCLUSION: Our study demonstrated a rapid decline in the percentage of patients treated with ESAs after changes to reimbursement policy, but not after warnings about use. Reimbursement restrictions of other overused or off-label drugs may help reduce health care expenditures.
Authors: Karen E Lasser; Paul D Allen; Steffie J Woolhandler; David U Himmelstein; Sidney M Wolfe; David H Bor Journal: JAMA Date: 2002-05-01 Impact factor: 56.272
Authors: Charles L Bennett; June M McKoy; Michael Henke; Samuel M Silver; Iain C MacDougall; Gunnar Birgegård; Stefano Luminari; Nicole Casadevall; Huub Schellekens; Oliver Sartor; Stephen Y Lai; James O Armitage Journal: Oncology (Williston Park) Date: 2010-03 Impact factor: 2.990
Authors: Alessandra Ferrajoli; Aman U Buzdar; Yvette Dejesus; Lee Cheng; Laura B Michaud; Maria A Rodriguez Journal: Cancer Date: 2011-01-24 Impact factor: 6.860
Authors: Michael Henke; Roland Laszig; Christian Rübe; Ulrich Schäfer; Klaus-Dieter Haase; Burkhard Schilcher; Stephan Mose; Karl T Beer; Ulrich Burger; Chris Dougherty; Hermann Frommhold Journal: Lancet Date: 2003-10-18 Impact factor: 79.321
Authors: Johan Vansteenkiste; Robert Pirker; Bartomeu Massuti; Fernando Barata; Albert Font; Michael Fiegl; Salvatore Siena; Jenni Gateley; Dianne Tomita; Alan B Colowick; Jaromir Musil Journal: J Natl Cancer Inst Date: 2002-08-21 Impact factor: 13.506
Authors: Melissa K Accordino; Jason D Wright; Sowmya Vasan; Alfred I Neugut; Grace C Hillyer; Jim C Hu; Dawn L Hershman Journal: J Clin Oncol Date: 2016-05-09 Impact factor: 44.544
Authors: John Bian; Brian Chen; Dawn L Hershman; Norman Marks; LeAnn Norris; Richard Schulz; Charles L Bennett Journal: J Clin Oncol Date: 2017-04-25 Impact factor: 44.544